Answers are grounded in this paper and cite their sources.
Shows sustained response in B-cell depleted patient, suggesting prolonged antiviral treatment may be necessary.
We provide detailed clinical, virological, and immunological data of a B-cell-depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.
No takes yet. Share an insight, caveat, or question.
Malsy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: